WHO Issues Warning Over Critical Scarcity of Obesity Medications
Fewer than a tenth of people that would benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it issues its inaugural recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.
According to estimates, over two billion could be obese by 2030 if no action is taken.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be treated with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the jabs that can help people shift considerable weight, notes the organization.
Skinny Jab Shortage
Despite the present most optimistic scenario, the manufacturing of such drugs could only cover about 100 million people – fewer than 10% of the global need, according to the WHO.
The recommendation calls on nations and manufacturers to widen access, by strategies like patent sharing.
A patent on semaglutide – the core component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, suppress the appetite and boost satiety so people consume fewer calories.
People usually start to lose weight within a few weeks of commencing the regular doses.
Studies points to people may see weight return after a year of stopping the treatment, when their normal appetite resume.
To be overweight or obese elevates your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity impacts individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, as per the health agency.
